{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:37:42Z","timestamp":1791999462521,"version":"4.4.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,17]],"date-time":"2024-08-17T00:00:00Z","timestamp":1723852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,8,17]],"date-time":"2024-08-17T00:00:00Z","timestamp":1723852800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004410","name":"T\u00fcrkiye Bilimsel ve Teknolojik Ara\u015ft\u0131rma Kurumu","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004410","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-69324-4","type":"journal-article","created":{"date-parts":[[2024,8,17]],"date-time":"2024-08-17T05:02:37Z","timestamp":1723870957000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Neuroprotective effects of L-Dopa-modified zinc oxide nanoparticles on the rat model of 6-OHDA-\u0131nduced Parkinson\u2019s disease"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6719-7077","authenticated-orcid":false,"given":"Yesim","family":"Yeni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u0131d\u0131ka","family":"Genc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammed Sait","family":"Ertugrul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayrunnisa","family":"Nadaroglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arzu","family":"Gezer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali Sefa","family":"Mendil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet","family":"Hac\u0131muftuoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,17]]},"reference":[{"issue":"3","key":"69324_CR1","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1097\/00005072-199305000-00001","volume":"52","author":"MS Pollanen","year":"1993","unstructured":"Pollanen, M. S., Dickson, D. W. & Bergeron, C. Pathology and biology of the Lewy body. J. Neuropathol. Exp. Neurol. 52(3), 183\u2013191 (1993).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"69324_CR2","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2174\/156652307780363125","volume":"7","author":"T Carlsson","year":"2007","unstructured":"Carlsson, T., Bjorklund, T. & Kirik, D. Restoration of the striatal dopamine synthesis for Parkinson\u2019s disease: Viral vectormediated enzyme replacement strategy. Curr. Gene Ther. 7, 109\u2013120 (2007).","journal-title":"Curr. Gene Ther."},{"issue":"2","key":"69324_CR3","doi-asserted-by":"publisher","first-page":"126","DOI":"10.4314\/njm.v19i2.56496","volume":"19","author":"FK Salawu","year":"2010","unstructured":"Salawu, F. K., Danburam, A. & Olokoba, A. B. Non-motor symptoms of Parkinson\u2019s disease: Diagnosis and management. Niger. J. Med. 19(2), 126\u2013131 (2010).","journal-title":"Niger. J. Med."},{"key":"69324_CR4","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1111\/jnc.13691","volume":"139","author":"S Sveinbjornsdottir","year":"2016","unstructured":"Sveinbjornsdottir, S. The clinical symptoms of Parkinson\u2019s disease. J. Neurochem. 139, 318\u2013324 (2016).","journal-title":"J. Neurochem."},{"key":"69324_CR5","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.drudis.2015.02.009","volume":"20","author":"G Leyva-G\u00f3mez","year":"2015","unstructured":"Leyva-G\u00f3mez, G. et al. Nanoparticle technology for treatment of Parkinson\u2019s disease: The role of surface phenomena in reaching the brain. Drug Discov. Today 20, 824\u2013837 (2015).","journal-title":"Drug Discov. Today"},{"issue":"1","key":"69324_CR6","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/mds.26125","volume":"30","author":"CC Aquino","year":"2015","unstructured":"Aquino, C. C. & Fox, S. H. Clinical spectrum of levodopa-induced complications. Mov. Disord. 30(1), 80\u201389 (2015).","journal-title":"Mov. Disord."},{"key":"69324_CR7","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S1353-8020(03)00059-2","volume":"10","author":"JM Garc\u00eda-Moreno","year":"2003","unstructured":"Garc\u00eda-Moreno, J. M., P\u00e1ramo, L. & Chacon, J. Oral L-dopa solution therapy of menstrual-related fluctuations in Parkinson\u2019s disease. Parkinsonism Relat. Disord. 10, 53\u201354 (2003).","journal-title":"Parkinsonism Relat. Disord."},{"issue":"16","key":"69324_CR8","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1001\/jama.2014.3654","volume":"311","author":"BS Connolly","year":"2014","unstructured":"Connolly, B. S. & Lang, A. E. Pharmacological treatment of Parkinson disease: A review. JAMA 311(16), 1670\u20131683 (2014).","journal-title":"JAMA"},{"key":"69324_CR9","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.arr.2013.12.009","volume":"13","author":"M Bisaglia","year":"2014","unstructured":"Bisaglia, M., Filograna, R., Beltramini, M. & Bubacco, L. Are dopamine derivatives implicated in the pathogenesis of Parkinson\u2019s disease? Ageing Res. Rev. 13, 107\u2013114 (2014).","journal-title":"Ageing Res. Rev."},{"key":"69324_CR10","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.pharmthera.2014.06.006","volume":"144","author":"DS Goldstein","year":"2014","unstructured":"Goldstein, D. S., Kopina, J. & Sharabi, Y. Catecholamine autotoxicity. Implications for pharmacology and therapeutics of Parkinson disease and related disorders. Pharmacol. Ther. 144, 268\u2013282 (2014).","journal-title":"Pharmacol. Ther."},{"key":"69324_CR11","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.jconrel.2015.08.039","volume":"219","author":"KA Ross","year":"2015","unstructured":"Ross, K. A. et al. Nano-enabled delivery of diverse payloads across complex biological barriers. J. Control Release 219, 548\u2013559 (2015).","journal-title":"J. Control Release"},{"key":"69324_CR12","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1517\/17425247.2015.1036738","volume":"12","author":"PU Richard","year":"2015","unstructured":"Richard, P. U. et al. New concepts to fight oxidative stress: Nanosized three-dimensional supramolecular antioxidant assemblies. Expert. Opin. Drug Deliv. 12, 1527\u20131545 (2015).","journal-title":"Expert. Opin. Drug Deliv."},{"key":"69324_CR13","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.neuint.2015.08.011","volume":"89","author":"R Sandhir","year":"2015","unstructured":"Sandhir, R., Yadav, A., Sunkaria, A. & Singhal, N. Nano-antioxidants: An emerging strategy for intervention against neurodegenerative conditions. Neurochem. Int. 89, 209\u2013226 (2015).","journal-title":"Neurochem. Int."},{"key":"69324_CR14","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.2147\/IJN.S130908","volume":"12","author":"P Marcianes","year":"2017","unstructured":"Marcianes, P. et al. Surface-modified gatifloxacin nanoparticles with potential for treating central nervous system tuberculosis. Int. J. Nanomed. 12, 1959\u20131968 (2017).","journal-title":"Int. J. Nanomed."},{"key":"69324_CR15","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s40824-019-0166-x","volume":"23","author":"D Chenthamara","year":"2019","unstructured":"Chenthamara, D. et al. Therapeutic efficacy of nanoparticles and routes of administration. Biomater. Res. 23, 20 (2019).","journal-title":"Biomater. Res."},{"issue":"1","key":"69324_CR16","doi-asserted-by":"publisher","first-page":"26","DOI":"10.4103\/0974-9233.106384","volume":"20","author":"Q Xu","year":"2013","unstructured":"Xu, Q., Kambhampati, S. P. & Kannan, R. M. Nanotechnology approaches for ocular drug delivery. Middle East Afr. J. Ophthalmol. 20(1), 26\u201337 (2013).","journal-title":"Middle East Afr. J. Ophthalmol."},{"issue":"8","key":"69324_CR17","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.1007\/s12274-020-3280-0","volume":"14","author":"T Nie","year":"2021","unstructured":"Nie, T. et al. Non-invasive delivery of levodopa-loaded nanoparticles to the brain via lymphatic vasculature to enhance treatment of Parkinson\u2019s disease. Nano Res. 14(8), 2749\u20132761 (2021).","journal-title":"Nano Res."},{"key":"69324_CR18","first-page":"36","volume":"66","author":"M Khedr","year":"2020","unstructured":"Khedr, M. et al. Neurobehavioural effect of zinc oxide nanoparticles and its conventional form on adult male rats and their pups. Alex. J. Vet. Sci. 66, 36 (2020).","journal-title":"Alex. J. Vet. Sci."},{"key":"69324_CR19","doi-asserted-by":"publisher","first-page":"175909142311559","DOI":"10.1177\/17590914231155976","volume":"15","author":"GC Nascimento","year":"2023","unstructured":"Nascimento, G. C. et al. Dynamic involvement of striatal NG2-glia in L-DOPA induced dyskinesia in Parkinsonian rats: Effects of doxycycline. ASN Neuro 15, 17590914231155976 (2023).","journal-title":"ASN Neuro"},{"issue":"11","key":"69324_CR20","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.3390\/pharmaceutics13111937","volume":"13","author":"S Abdulmalek","year":"2021","unstructured":"Abdulmalek, S., Nasef, M., Awad, D. & Balbaa, M. Protective effect of natural antioxidant, curcumin nanoparticles, and zinc oxide nanoparticles against type 2 diabetes-promoted hippocampal neurotoxicity in rats. Pharmaceutics 13(11), 1937 (2021).","journal-title":"Pharmaceutics"},{"key":"69324_CR21","volume-title":"The Rat Brain in Stereotaxic Coordinates: Hard Cover Edition","author":"G Paxinos","year":"2006","unstructured":"Paxinos, G. & Watson, C. The Rat Brain in Stereotaxic Coordinates: Hard Cover Edition (Elsevier, 2006)."},{"key":"69324_CR22","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/j.1365-201X.1971.tb11000.x","volume":"367","author":"U Ungerstedt","year":"1971","unstructured":"Ungerstedt, U. Postsynaptic supersensitivity after 6-hydroxy-dopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiol. Scand. Suppl. 367, 69\u201393 (1971).","journal-title":"Acta Physiol. Scand. Suppl."},{"issue":"1\u20133","key":"69324_CR23","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ejphar.2008.10.005","volume":"600","author":"F Jin","year":"2008","unstructured":"Jin, F. et al. Neuroprotective effect of resveratrol on 6-OHDA-induced Parkinson\u2019s disease in rats. Eur. J. Pharmacol. 600(1\u20133), 78\u201382 (2008).","journal-title":"Eur. J. Pharmacol."},{"issue":"2","key":"69324_CR24","doi-asserted-by":"publisher","first-page":"246","DOI":"10.3390\/jpm12020246","volume":"12","author":"Y Yeni","year":"2022","unstructured":"Yeni, Y. et al. A selective histamine H4 receptor antagonist, JNJ7777120, role on glutamate transporter activity in chronic depression. J. Pers. Med. 12(2), 246 (2022).","journal-title":"J. Pers. Med."},{"key":"69324_CR25","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.bbr.2011.12.007","volume":"230","author":"KE Glajch","year":"2012","unstructured":"Glajch, K. E., Fleming, S. M., Surmeier, D. J. & Osten, P. Sensorimotor assessment of the unilateral 6-hydroxydopamine mouse model of Parkinson\u2019s disease. Behav. Brain Res. 230, 309\u2013316 (2012).","journal-title":"Behav. Brain Res."},{"key":"69324_CR26","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1097\/FBP.0000000000000441","volume":"30","author":"A Hamadjida","year":"2019","unstructured":"Hamadjida, A., Frouni, I., Kwan, C. & Huot, P. Classic animal models of Parkinson\u2019s disease: A historical perspective. Behav. Pharmacol. 30, 291\u2013310 (2019).","journal-title":"Behav. Pharmacol."},{"key":"69324_CR27","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(T)(\u2212Delta Delta C) method. Methods 25, 402\u2013408 (2001).","journal-title":"Methods"},{"key":"69324_CR28","doi-asserted-by":"publisher","first-page":"4340","DOI":"10.3390\/ijms13044340","volume":"13","author":"MR Arefi","year":"2012","unstructured":"Arefi, M. R. & Rezaei-Zarchi, S. Synthesis of zinc oxide nanoparticles and their effect on the compressive strength and setting time of self-compacted concrete paste as cementitious composites. Int. J. Mol. Sci. 13, 4340\u20134350 (2012).","journal-title":"Int. J. Mol. Sci."},{"key":"69324_CR29","first-page":"129","volume":"01","author":"K Prasad","year":"2009","unstructured":"Prasad, K. & Jha, K. A. ZnO nanoparticles: Synthesis and adsorption study. Nat Sci. 01, 129\u2013135 (2009).","journal-title":"Nat Sci."},{"key":"69324_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2017\/8348507","volume":"2017","author":"SP Rajendran","year":"2017","unstructured":"Rajendran, S. P. & Sengodan, K. Synthesis and characterization of zinc oxide and iron oxide nanoparticles using sesbania grandiflora leaf extract as reducing agent. J. Nanosci. 2017, 1\u20137 (2017).","journal-title":"J. Nanosci."},{"key":"69324_CR31","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s11240-018-1512-8","volume":"136","author":"OB Nalci","year":"2019","unstructured":"Nalci, O. B. et al. Effects of ZnO, CuO and \u03b3-Fe3O4 nanoparticles on mature embryo culture of wheat (Triticum aestivum L.). Plant Cell Tissue Organ Cult. 136, 269\u2013277 (2019).","journal-title":"Plant Cell Tissue Organ Cult."},{"key":"69324_CR32","first-page":"775","volume":"17","author":"H Nadaroglu","year":"2020","unstructured":"Nadaroglu, H. & Alayli, A. Highly sensitive glucose sensor based on ZnO NPs as a biomimetic enzyme. Biosci. Res. 17, 775\u2013785 (2020).","journal-title":"Biosci. Res."},{"issue":"20","key":"69324_CR33","doi-asserted-by":"publisher","first-page":"4178","DOI":"10.1039\/D1TB00481F","volume":"9","author":"V Morales","year":"2021","unstructured":"Morales, V. et al. L-Dopa release from mesoporous silica nanoparticles engineered through the concept of drug-structure-directing agents for Parkinson\u2019s disease. J. Mater. Chem. B 9(20), 4178\u20134189 (2021).","journal-title":"J. Mater. Chem. B"},{"key":"69324_CR34","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1212\/WNL.0b013e318232ab4c","volume":"77","author":"L Parkkinen","year":"2011","unstructured":"Parkkinen, L. et al. Does levodopa accelerate the pathologic process in Parkinson disease brain? Neurology 77, 1420\u20131426 (2011).","journal-title":"Neurology"},{"key":"69324_CR35","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.2147\/IJN.S39740","volume":"8","author":"AU Kura","year":"2013","unstructured":"Kura, A. U. et al. Development of a controlled-release anti-Parkinsonian nano delivery system using levodopa as the active agent. Int. J. Nanomed. 8, 1103\u20131110 (2013).","journal-title":"Int. J. Nanomed."},{"key":"69324_CR36","doi-asserted-by":"publisher","first-page":"19216","DOI":"10.1021\/jp205050k","volume":"115","author":"M Jaber","year":"2011","unstructured":"Jaber, M. et al. Fate of L-DOPA in the presence of inorganic matrices: Vectorization or composite material formation? J. Phys. Chem. C 115, 19216\u201319225 (2011).","journal-title":"J. Phys. Chem. C"},{"key":"69324_CR37","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/bcpt.12669","volume":"120","author":"RB Souza","year":"2017","unstructured":"Souza, R. B. et al. Neuroprotective effects of sulphated agaran from marine alga Gracilaria cornea in rat 6-hydroxydopamine Parkinson\u2019s disease model: Behavioural, neurochemical and transcriptional alterations. Basic Clin. Pharmacol. Toxicol. 120, 159\u2013170 (2017).","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"69324_CR38","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/587418","volume":"2013","author":"JR Richardson","year":"2013","unstructured":"Richardson, J. R. & Hossain, M. M. Microglial ion channels as potential targets for neuroprotection in Parkinson\u2019s disease. Neural Plast. 2013, 587418 (2013).","journal-title":"Neural Plast."},{"key":"69324_CR39","first-page":"3356","volume":"17","author":"RJ Su","year":"2018","unstructured":"Su, R. J. et al. Time-course behavioral features are correlated with Parkinson\u2019s disease-associated pathology in a 6-hydroxydopamine hemiparkinsonian rat model. Mol. Med. Rep. 17, 3356\u20133363 (2018).","journal-title":"Mol. Med. Rep."},{"key":"69324_CR40","first-page":"21","volume":"43","author":"DP de Araujo","year":"2013","unstructured":"de Araujo, D. P. et al. Behavioral and neurochemical effects of alpha-lipoic Acid in the model of Parkinson\u2019s disease induced by unilateral stereotaxic injection of 6-OHDA in rat. Evid. Based Complement Alternat. Med. 43, 21\u201334 (2013).","journal-title":"Evid. Based Complement Alternat. Med."},{"key":"69324_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12974-018-1266-6","volume":"15","author":"LA Lima","year":"2018","unstructured":"Lima, L. A. et al. Vitamin D protects dopaminergic neurons against neuroinflammation and oxidative stress in hemiparkinsonian rats. J. Neuroinflamm. 15, 1\u201311 (2018).","journal-title":"J. Neuroinflamm."},{"key":"69324_CR42","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.neures.2017.10.006","volume":"133","author":"S Singh","year":"2018","unstructured":"Singh, S. & Kumar, P. Piperine in combination with quercetin halt 6-OHDA induced neurodegeneration in experimental rats: Biochemical and neurochemical evidences. Neurosci. Res. 133, 38\u201347 (2018).","journal-title":"Neurosci. Res."},{"key":"69324_CR43","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1124\/pr.108.000166","volume":"60","author":"F Ferraguti","year":"2008","unstructured":"Ferraguti, F., Crepaldi, L. & Nicoletti, F. Metabotropic glutamate 1 receptor: Current concepts and perspectives. Pharmacol. Rev. 60, 536\u2013581 (2008).","journal-title":"Pharmacol. Rev."},{"key":"69324_CR44","first-page":"367","volume":"21","author":"G Sengul","year":"2011","unstructured":"Sengul, G. et al. Neuroprotective effect of ACE inhibitors in glutamate-induced neurotoxicity: Rat neuron culture study. Turk. Neurosurg. 21, 367\u2013371 (2011).","journal-title":"Turk. Neurosurg."},{"key":"69324_CR45","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1002\/cne.21852","volume":"511","author":"EKY Chung","year":"2008","unstructured":"Chung, E. K. Y., Chen, L. W., Chan, Y. S. & Yung, K. K. L. Downregulation of glial glutamate transporters after dopamine denervation in the striatum of 6-hydroxydopamine-lesioned rats. J. Comp. Neurol. 511, 421\u2013437 (2008).","journal-title":"J. Comp. Neurol."},{"key":"69324_CR46","doi-asserted-by":"publisher","first-page":"8941327","DOI":"10.1155\/2016\/8941327","volume":"2016","author":"YL Zhang","year":"2016","unstructured":"Zhang, Y. L., Tan, F., Xu, P. Y. & Qu, S. G. Recent advance in the relationship between excitatory amino acid transporters and Parkinson\u2019s disease. Neural Plast. 2016, 8941327 (2016).","journal-title":"Neural Plast."},{"key":"69324_CR47","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.expneurol.2012.01.012","volume":"234","author":"MF Salvatore","year":"2012","unstructured":"Salvatore, M. F., Davis, R. W., Arnold, J. C. & Chotibut, T. Transient striatal GLT-1 blockade increases EAAC1 expression, glutamate reuptake, and decreases tyrosine hydroxylase phosphorylation at ser (19). Exp. Neurol. 234, 428\u2013436 (2012).","journal-title":"Exp. Neurol."},{"key":"69324_CR48","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.nbd.2014.01.011","volume":"65","author":"M Assous","year":"2014","unstructured":"Assous, M. et al. Progressive Parkinsonism by acute dysfunction of excitatory amino acid transporters in the rat substantia nigra. Neurobiol. Dis. 65, 69\u201381 (2014).","journal-title":"Neurobiol. Dis."},{"key":"69324_CR49","first-page":"261","volume":"2","author":"DS Gary","year":"2002","unstructured":"Gary, D. S. & Mattson, M. P. PTEN regulates Akt kinase activity in hippocampal neurons and increases their sensitivity to glutamate and apoptosis. N\u00f6romol. Med. 2, 261\u2013269 (2002).","journal-title":"N\u00f6romol. Med."},{"key":"69324_CR50","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/S0169-328X(99)00259-4","volume":"73","author":"S Kyrylenko","year":"1999","unstructured":"Kyrylenko, S., Roschier, M., Korhonen, P. & Salminen, A. Regulation of PTEN expression in neuronal apoptosis. Brain Res. Mol. Brain Res. 73, 198\u2013202 (1999).","journal-title":"Brain Res. Mol. Brain Res."},{"issue":"1","key":"69324_CR51","doi-asserted-by":"publisher","first-page":"43","DOI":"10.32598\/bcn.12.6.88.7","volume":"12","author":"J Ghalami","year":"2021","unstructured":"Ghalami, J. et al. Paeonol protection against intrastriatal 6-hydroxydopamine rat model of Parkinson\u2019s disease. Basic Clin. Neurosci. 12(1), 43\u201356 (2021).","journal-title":"Basic Clin. Neurosci."},{"key":"69324_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.nantod.2020.101027","volume":"36","author":"Y-Q Liu","year":"2021","unstructured":"Liu, Y.-Q. et al. Nanozyme scavenging ROS for prevention of pathologic \u03b1-synuclein transmission in Parkinson\u2019s disease. Nano Today 36, 101027 (2021).","journal-title":"Nano Today"},{"issue":"7","key":"69324_CR53","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.7460","volume":"23","author":"RZ Hamza","year":"2019","unstructured":"Hamza, R. Z., Al-Salmi, F. A. & El-Shenawy, N. S. Evaluation of the effects of the green nanoparticles zinc oxide on monosodium glutamate-induced toxicity in the brain of rats. PeerJ 23(7), e7460 (2019).","journal-title":"PeerJ"},{"issue":"9","key":"69324_CR54","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1080\/02772248.2012.731290","volume":"94","author":"S Gantedi","year":"2012","unstructured":"Gantedi, S. & Anreddy, R. N. R. Toxicological studies of zinc oxide nanomaterials in rats. Toxicol. Environ. Chem. 94(9), 1768\u20131779 (2012).","journal-title":"Toxicol. Environ. Chem."},{"issue":"3","key":"69324_CR55","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s00401-007-0244-3","volume":"114","author":"H Braak","year":"2007","unstructured":"Braak, H., Sastre, M. & Del Tredici, K. Development of alpha-synuclein immunoreactive astrocytes in the forebrain parallels stages of intraneuronal pathology in sporadic Parkinson\u2019s disease. Acta Neuropathol. 114(3), 231\u2013241 (2007).","journal-title":"Acta Neuropathol."},{"issue":"2","key":"69324_CR56","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s12035-012-8340-3","volume":"47","author":"L Fellner","year":"2013","unstructured":"Fellner, L. & Stefanova, N. The role of glia in alpha-synucleinopathies. Mol Neurobiol. 47(2), 575\u2013586 (2013).","journal-title":"Mol Neurobiol."},{"issue":"6","key":"69324_CR57","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0039465","volume":"7","author":"E Angot","year":"2012","unstructured":"Angot, E. et al. Alpha-synuclein cell-to-cell transfer and seeding in grafted dopaminergic neurons in vivo. PLoS ONE 7(6), e39465 (2012).","journal-title":"PLoS ONE"},{"key":"69324_CR58","doi-asserted-by":"publisher","first-page":"S62","DOI":"10.1016\/S1353-8020(13)70017-8","volume":"20","author":"H McCann","year":"2014","unstructured":"McCann, H., Stevens, C. H., Cartwright, H. & Halliday, G. M. a-Synucleinopathy phenotypes. Parkinsonism Relat. Disord. 20, S62\u2013S67 (2014).","journal-title":"Parkinsonism Relat. Disord."},{"issue":"9","key":"69324_CR59","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1016\/j.freeradbiomed.2008.08.002","volume":"45","author":"S Vali","year":"2008","unstructured":"Vali, S. et al. Insights into the effects of alpha-synuclein expression and proteasome inhibition on glutathione metabolism through a dynamic in silico model of Parkinson\u2019s disease: Validation by cell culture data. Free Radic. Biol. Med. 45(9), 1290\u20131301 (2008).","journal-title":"Free Radic. Biol. Med."},{"issue":"2","key":"69324_CR60","doi-asserted-by":"publisher","first-page":"103","DOI":"10.5607\/en.2015.24.2.103","volume":"24","author":"HE Moon","year":"2015","unstructured":"Moon, H. E. & Paek, S. H. Mitochondrial dysfunction in Parkinson\u2019s disease. Exp. Neurobiol. 24(2), 103\u2013116 (2015).","journal-title":"Exp. Neurobiol."},{"key":"69324_CR61","doi-asserted-by":"publisher","first-page":"2923","DOI":"10.1007\/s11064-016-2011-0","volume":"41","author":"XS Gu","year":"2016","unstructured":"Gu, X. S. et al. Neuroprotective effects of paeoniflorin on 6-OHDA-lesioned rat model of Parkinson\u2019s disease. Neurochem. Res. 41, 2923\u20132936 (2016).","journal-title":"Neurochem. Res."},{"key":"69324_CR62","volume":"2014","author":"I Calou","year":"2014","unstructured":"Calou, I. et al. Neuroprotective properties of a standardized extract from Myracrodruon urundeuva Fr. All. (Aroeira-Do-Sertao), as evaluated by a Parkinson\u2019s disease model in rats. Parkinsons Dis. 2014, 519615 (2014).","journal-title":"Parkinsons Dis."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-69324-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-69324-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-69324-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T09:06:57Z","timestamp":1724144817000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-69324-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,17]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["69324"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-69324-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,17]]},"assertion":[{"value":"17 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19077"}}